Heat Biologics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York

DURHAM, NC / ACCESSWIRE / September 7, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, will present at the 19th annual Rodman & Renshaw Global Investment conference on Tuesday, Sept. 12, 2017 at the Lotte New York Palace Hotel in New York.

Jeff Wolf, CEO of Heat, will provide an overview of the Company's business during the live presentation, and will be available to participate in one-on-one meetings with investors registered to attend the conference.

Mr. Wolf will be speaking from 4:40 p.m. - 5:05 p.m. EDT, with the presentation available to watch live at www.rodmanevents.comfor those who cannot attend.

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer. We take a combination approach to our therapeutic treatments by incorporating immune system modulators and other drugs into our cancer-fighting therapies. This enables T cells to be activated and expanded so they can potentially zero in on cancer cells and destroy them. Our T Cell Activation Platform (TCAP) produces therapies from our ImPACT® and ComPACT™ systems derived from allogeneic cancer cell lines selected for a broad sampling of tumor proteins common amongst all cancers. We can also combine our TCAP system with existing T cell checkpoint inhibitors and co-stimulators in a single treatment. This offers the potential benefit of combination immunotherapy without the need for multiple, independent biologic products. We are currently enrolling patients in our Phase 2 clinical trial for non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). We also have numerous pre-clinical programs underway at various stages of development. For more information, please visit www.heatbio.com.

Contact

For Media and Investor Inquiries
Melissa M Conger
Heat Biologics
+1 919 289 4017
mconger@heatbio.com

SOURCE: Heat Biologics, Inc.

Released September 7, 2017